Format

Send to

Choose Destination
Neurology. 2007 Jul 17;69(3):283-90.

Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease.

Author information

1
Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143-1207, USA. aboxer@memory.ucsf.edu

Abstract

OBJECTIVE:

To compare the in vivo uptake of two amyloid-binding PET agents, PIB and FDDNP, in human subjects with a prion protein (PrP) gene (PRNP) mutation that produces a clinical syndrome similar to Alzheimer disease (AD).

BACKGROUND:

Amyloid imaging with specific PET ligands offers great promise for early detection and differential diagnosis of AD. Genetic forms of prion disease can present with clinical features that resemble AD, and at autopsy may show deposition of mutant PrP-amyloid. FDDNP binds to PrP-amyloid in postmortem human specimens, but has not been reported in vivo in prion disease. The ability of PIB to bind PrP-amyloid is not known.

METHODS:

Two brothers with a 6 octapeptide repeat insertion mutation (6-OPRI) in the PRNP gene underwent clinical, structural MRI, and FDG-PET evaluations. One brother received a PIB-PET evaluation, while the other received an FDDNP-PET scan. PET results were compared with five normal subjects and five individuals with AD scanned with either agent.

RESULTS:

PIB uptake was similar to controls in one brother, while FDDNP uptake was intermediate between AD and controls in the other brother.

CONCLUSIONS:

Different amyloid-binding agents may have differential sensitivity to prion-related brain pathology. A combination of amyloid imaging agents may be useful in the diagnosis of early-onset dementia.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center